TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01470027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 900mg NAC effervescent tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 900mg NAC effervescent tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: effervescent tablets
Study: NCT03402243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol ban on cigarettes
Description: Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol ban on cigarettes and e-cigarettes
Description: Participants will have neither menthol flavored cigarettes or e-cigarettes available

Intervention type: OTHER
Group type: OTHER
Intervention: No menthol ban
Description: Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
Study: NCT01993524

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: antibiotic plus probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: antibiotic plus placebo
Study: NCT01040130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on exercise endurance time in COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on exercise endurance time in COPD patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of low and high dose and placebo on exercise endurance time in COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) Placebo
Description: Placebo that represents olodaterol
Study: NCT00881725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
Study: NCT01584063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy MOMs Healthy Lifestyle Intervention
Description: These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
Study: NCT02083523

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview with Normative Feedback
Description: NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
Study: NCT03727893

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Roller-based Intervention Group (IG)
Description: A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (CG)
Description: A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
Study: NCT02863016

Intervention type: DEVICE
Intervention: SelectBag One
Description: Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.

Intervention type: DEVICE
Intervention: SelectBag One
Description: Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
Study: NCT03207750

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Study: NCT02632747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matching empagliflozin)
Description: Placebo will be taken once daily
Study: NCT04492046

Intervention type: OTHER
Intervention: Manual Lymph Drainage
Description: Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.

Intervention type: OTHER
Intervention: Bandaging
Description: Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
Study: NCT02388321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Study: NCT02462395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software.
Study: NCT01972061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot stimulation
Description: Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot stimulation
Description: Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot stimulation
Description: Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
Study: NCT01972061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot stimulation
Description: Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
Study: NCT00289341

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: vaccine vehicle only
Description: Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/LNCaP
Description: Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
Study: NCT04181034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Family Life Program Positive Youth Development (PYD) program
Description: Home visiting program for pregnant and parenting teens with PYD component

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent Family Life Program (AFLP)
Description: Home visiting program for pregnant and parenting teens
Study: NCT01334697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human cardiotrophin-1
Description: Single dose intravenous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose intravenous administration
Study: NCT02358486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 \~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
Study: NCT02233712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study: NCT03152305

Intervention type: OTHER
Intervention: Intracranial pressure variations
Description: Self-measure of ICP will be performed outside and during menstrual migraine attacks.
Study: NCT02632747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: Ramipril will be taken once or twice daily
Study: NCT03821428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Needling of P6 and CV24 points

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo acupuncture needles to the areas, where the acupoints are situated
Study: NCT01487330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
Study: NCT03223389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C-8 dietary oil
Description: Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C-8 dietary oil
Description: Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricaprylin
Description: Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricaprylin
Description: Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
Study: NCT01286818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab (IMC-1121B)
Description: Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofolinate
Description: IV infusion, 200 mg/m² every 2 weeks
Study: NCT02282826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02450279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: technetium-99m - Diethylenetriaminepentaacetic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: technetium-99m - Diethylenetriaminepentaacetic acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating-mesh nebulizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Planar scintigraphy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Planar scintigraphy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative spirometry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative spirometry
Study: NCT02282826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acyclovir
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT04024280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
Study: NCT01286818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
Study: NCT01504438

Intervention type: DEVICE
Group type: OTHER
Intervention: Salto-Talaris Total Ankle Replacement
Description: Salto-Talaris Total ankle replacement surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: STAR Total Ankle Replacement
Description: STAR Total Ankle Replacement
Study: NCT02087800

Intervention type: BEHAVIORAL
Intervention: F phase lab session
Description: F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.

Intervention type: BEHAVIORAL
Intervention: F phase lab session
Description: F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.

Intervention type: BEHAVIORAL
Intervention: L phase lab session
Description: L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.

Intervention type: BEHAVIORAL
Intervention: L phase lab session
Description: L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
Study: NCT03178734

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter vs Self-Contained Valved Catheter
Description: This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter vs Self-Contained Valved Catheter
Description: This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
Study: NCT03210142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvenous hypoglossal nerve stimulation
Description: Transvenous hypoglossal nerve stimulation to open upper airway.
Study: NCT03541668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human urokinase
Description: Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
Study: NCT02291172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention JEP
Description: A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
Study: NCT04113564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Study: NCT01950195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT04653701

Intervention type: COMBINATION_PRODUCT
Intervention: Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter
Description: We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
Study: NCT02607293

Intervention type: DRUG
Intervention: Gonal-f®
Description: Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
Study: NCT03151226

Intervention type: DEVICE
Group type: OTHER
Intervention: Capnography monitoring
Description: capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
Study: NCT04498936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Ledipasvir
Description: Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
Study: NCT01491243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive treatment with sodium bicarbonate
Description: i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment with saline infusion
Description: i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings